A Benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making

Drug Information Journal

Volumn 45, Issue 6, 2011, Pages 749-757

  Sashegyi, Andreas ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Benefit risk; Blinding; Data monitoring committee; Multiattribute model

Indexed keywords

DECISION MAKING; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 84864824607     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151104500511     Document Type: Review

References (7)

1. Ellenberg SFleming TDeMets D.West Sussex, UK: Wiley; 2002:.
2. CHMP. Guideline on data monitoring committees. 2005. http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf (accessed February 3, 2011).
3. Food and Drug Administration. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees. 2002. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf (accessed February 3, 2011).
4. DeMets DL.Pocock SJ.Julian DG.The agonizing negative trend in monitoring of clinical trials.Lancet. 1999;354:1983-1988.
5. Sashegyi AI.Role of the data monitoring committee and sponsor in monitoring adaptive designs.Pharm Outsourcing. 2010;11:28-31.
6. Mussen F.Salek S.Walker S.A quantitative approach to benefit-risk assessment of medicines-part 1: The development of a new model using multi-criteria decision analysis.Pharmacoepidemiol Drug Saf. 2007;16:S2-S15.
7. Felli JC.Noel RA.Cavazzoni PA.A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.Med Decis Making. 2009;29:105-115.